{"disease":{"id":"secondary-immunodeficiency","name":"secondary immunodeficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02303093","title":"Non-Interventional Study on the Tolerability and Efficacy of IVIG","phase":"","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"Octapharma","has_results":true},{"nct_id":"NCT06980480","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":183,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06659588","title":"Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05879757","title":"Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03677557","title":"Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT03668288","title":"Tolerance and Patients' Satisfaction With IGHy","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"CHU de Reims","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}